Eli Lilly and Company (NYSE:LLY) Position Lowered by Roman Butler Fullerton & Co.

Roman Butler Fullerton & Co. decreased its holdings in Eli Lilly and Company (NYSE:LLY) by 1.8% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 9,788 shares of the company’s stock after selling 178 shares during the quarter. Eli Lilly and Company accounts for approximately 2.5% of Roman Butler Fullerton & Co.’s investment portfolio, making the stock its 6th largest holding. Roman Butler Fullerton & Co.’s holdings in Eli Lilly and Company were worth $6,257,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of the business. Fairfield Bush & CO. purchased a new position in Eli Lilly and Company in the first quarter valued at about $107,000. Roundview Capital LLC lifted its holdings in Eli Lilly and Company by 2.6% during the 1st quarter. Roundview Capital LLC now owns 2,056 shares of the company’s stock worth $589,000 after buying an additional 53 shares during the last quarter. Merit Financial Group LLC acquired a new stake in Eli Lilly and Company in the 1st quarter valued at about $210,000. NewEdge Advisors LLC lifted its holdings in Eli Lilly and Company by 9.9% during the 1st quarter. NewEdge Advisors LLC now owns 53,052 shares of the company’s stock worth $15,193,000 after buying an additional 4,774 shares in the last quarter. Finally, Barometer Capital Management Inc. bought a new position in Eli Lilly and Company in the 1st quarter valued at $561,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the sale, the insider now directly owns 99,333,810 shares of the company’s stock, valued at approximately $64,375,262,246.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.13% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on LLY shares. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. JPMorgan Chase & Co. boosted their price target on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a report on Friday, March 15th. Wells Fargo & Company upped their price objective on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. Truist Financial reiterated a “buy” rating and set a $850.00 target price on shares of Eli Lilly and Company in a report on Friday, March 22nd. Finally, Morgan Stanley increased their price target on Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a report on Friday, February 16th. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average target price of $728.05.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock traded down $1.39 during mid-day trading on Thursday, reaching $749.38. 293,968 shares of the company were exchanged, compared to its average volume of 3,047,469. The company has a fifty day simple moving average of $764.03 and a 200-day simple moving average of $657.67. The firm has a market cap of $712.03 billion, a PE ratio of 129.46, a PEG ratio of 1.63 and a beta of 0.34. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. Eli Lilly and Company has a 12 month low of $367.35 and a 12 month high of $800.78.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The firm had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. During the same period last year, the firm earned $2.09 EPS. The business’s quarterly revenue was up 28.1% compared to the same quarter last year. As a group, equities research analysts expect that Eli Lilly and Company will post 12.52 earnings per share for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.